Search Results
Your search for Colorectal matches 3165 pages
Showing 1201 - 1250Pembrolizumab for First-Line Treatment of Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
On June 29, 2020, pembrolizumab was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer.1 Supporting Efficacy Data Approval was based on findings in the randomized,...
NCCN Clinical Practice Guidelines in Oncology: 2020 Updates
In 1996, the National Comprehensive Cancer Network (NCCN) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 25th Annual Conference, which was held virtually during ...
Higher Prevalence of Germline Mutations Identified in Young Adults With Cancer
A new study has found that a higher-than-expected proportion of young adults with cancer harbor genetic germline mutations that have implications for treatment, surveillance, and other family members who may be at risk. Patients with “early-onset cancers”—cancers that typically do not occur in...
Expert Point of View: Juan W. Valle, MD
Invited discussant Juan W. Valle, MD, of the University of Manchester/The Christie, United Kingdom, reiterated the 50% response rate, the median progression-free survival of 7.1 months, and the median overall survival of 16.0 months achieved with entrectinib in patients who had gastrointestinal...
NTRK Fusions in Gastrointestinal Cancers: Rare but Responsive to Treatment
Although NTRK gene fusions occur in less than 5% of gastrointestinal cancers, it looks like they can be targeted successfully with NTRK inhibitors. In a pooled analysis of three clinical trials, 50% of such patients responded to entrectinib, in an updated analysis presented during the 2020 virtual...
Edward Chu, MD, MMS, to Lead Cancer Medicine at Albert Einstein College of Medicine and Montefiore Health System
Albert Einstein College of Medicine and Montefiore Health System recently announced that Edward Chu, MD, MMS, has been named Director of the National Cancer Institute-designated Albert Einstein Cancer Center, Vice President for Cancer Medicine at Montefiore Medicine, Professor of Medicine and of...
Measuring the Impact of the Plunge in Cancer Screenings During the COVID-19 Pandemic
As outbreaks of the COVID-19 pandemic spiked across the country earlier this year, federal health officials and cancer societies advised people to delay seeking routine cancer screenings, including mammograms and colonoscopies, to keep them out of medical centers and away from potential exposure to ...
A Brief Primer on Managing Anxiety in Older Adults With Cancer
Cancer-related anxiety has negative impacts on emotional, physical, and social well-being, with data indicating older patients are likely to remain undiagnosed, leading to poor outcomes. In this installment of The ASCO Post’s Integrative Oncology series, Drs. Trevino, Saracino, and Roth highlight...
Second-Look Surgery Plus HIPEC vs Surveillance for Patients at High Risk for Colorectal Peritoneal Metastases
In a French phase III trial (PROPHYLOCHIP–PRODIGE 15) reported in The Lancet Oncology, Goéré et al found that second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) did not improve disease-free survival vs standard surveillance in patients at high risk of developing colorectal...
Nationwide Trends Show Fewer Patients With Cancer in the United States Seeking Care Since Start of the COVID-19 Pandemic
Research published by London et al in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients seen for cancer-related care as the COVID-19 pandemic progressed during the first few months of 2020. The most significant decline was seen in encounters related to ...
Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?
Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).
Does Periodontal Disease Increase the Risk of Colorectal Cancer?
Periodontal disease was associated with an increased risk of two precursors of colorectal cancer, according to results of a study published by Lo et al in Cancer Prevention Research. “Periodontal disease is prevalent among adults, with periodontitis affecting more than 40% of the U.S. population,”...
Modeling Study Aims to Estimate the Effect of the COVID-19 Pandemic on Cancer Deaths in England
In a population-based modeling study reported in The Lancet Oncology, Maringe et al estimated that delays in diagnosis due to the COVID-19 pandemic could result in 3,291 to 3,621 additional deaths from breast, colorectal, esophageal, and lung cancers within 5 years. As stated by the investigators,...
Stacey A. Fedewa, PhD, on Cancers in Younger Populations: Current Trends
Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease in younger patients. Data show that colorectal cancer is increasing most rapidly, while breast cancer—the most common cancer...
Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries
LaSalle D. Leffall, Jr, MD, the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC, died on May 25, 2019, at the age of 89. The ASCO Post paid tribute to Dr. Leffall in its July 10, 2019, issue. Here, as part of our 10-Year Anniversary Series, we...
USC Norris Comprehensive Cancer Center Receives $5 Million for Cancer Drug Discoveries
The University of Southern California (USC) Norris Comprehensive Cancer Center, Keck Medicine of USC, and the Keck School of Medicine of USC announced a $5 million gift from the Rosalie and Harold Rae Brown Charitable Foundation. The gift was received from Harold R. Brown, trustee of the...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
In Keynote Lecture, Anthony Fauci, MD, Explores What We Know About COVID-19 and What’s Being Done to Combat It
Kicking off the American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer earlier this week, Anthony Fauci, MD, gave the keynote lecture, “Coronavirus Infections: More Than Just the Common Cold.” As Dr. Fauci told listeners, “[COVID-19]—and other infectious...
Adjuvant Chemotherapy vs Active Surveillance: Survival After Resection of Isolated Synchronous Colorectal Peritoneal Metastases
In a Dutch population-based observational cohort study reported in JAMA Oncology, Rovers et al found that adjuvant systemic chemotherapy was associated with improved overall survival vs active surveillance after upfront resection of isolated synchronous colorectal peritoneal metastases. Study...
Common Hypertension Medications May Also Reduce Risk of Colorectal Cancer
Medications commonly prescribed to treat high blood pressure may also reduce the risk of colorectal cancer, according to new research published by Cheung et al in the journal Hypertension. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are often prescribed...
Study Finds Young Adults With Cancer May Harbor Germline Mutations and Benefit From Germline Genetic Testing
According to the National Cancer Institute, each year, about 70,000 adolescents and young adults (AYAs)—those between the ages of 15 and39—are diagnosed with cancer.1 Evidence suggests that some cancers found in AYAs may have unique genetic and biologic features. The findings of a recent study by...
Expert Point of View: Christopher Leigh Hallemeier, MD
The invited discussant for the RAPIDO and PRODIGE 23 trials, Christopher Leigh Hallemeier, MD, Associate Professor of Radiation Oncology at the Mayo Clinic, Rochester, noted the standard approach to locally advanced rectal cancer has been, for the past 2 decades, a long course of chemoradiotherapy...
Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer
In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...
GI-Related Patient-Reported Outcomes in Individuals Receiving Chemoradiation for Anal Cancer
In a single-institution study reported in JCO Oncology Practice, Kouzy et al found that gastrointestinal (GI)-related patient-reported outcomes among those receiving chemoradiation for anal cancer improved vs baseline at 1 week after treatment initiation, were worse vs baseline at 5 weeks, but did...
Geographic Patterns of Early-Onset Colorectal Cancer Diagnoses in the United States
Over the past 3 decades, colorectal cancer survival in the United States has improved significantly, but in young people—particularly men diagnosed with colorectal cancer before age 50—incidence and mortality due to colorectal cancer are on the rise. Additionally, among patients with early-stage...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Rates of Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer Doubled by Pembrolizumab
Upfront treatment with immunotherapy not only improved results in a subset of patients with metastatic colorectal cancer, it doubled the rates of median progression-free survival. These findings—the first of their kind—arose from the interim analysis of the randomized open-label phase III...
Conference Highlights From the ASCO20 Virtual Scientific Program
The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
FDA Approves Pembrolizumab for the First-Line Treatment of MSI-H/dMMR Colorectal Cancer
On June 29, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer. KEYNOTE-177 Approval was based on...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
Integrating Physical Activity Into Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Accumulating evidence suggests the benefits of physical activity through the cancer continuum....
Seattle Cancer Care Alliance Opens New Clinic Dedicated to Gastrointestinal Cancer Care
Seattle Cancer Care Alliance (SCCA) announced the opening of a Gastrointestinal (GI) Care Neighborhood, a new cancer clinic aimed at improving the experience for patients with GI cancers, which features dedicated GI-related cancer care services on one floor of SCCA’s South Lake Union campus. “We...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
Improving Care for Women With Late-Stage Breast Cancer
The global toll of breast cancer on women is staggering. In 2018, nearly two million new breast cancer cases were diagnosed, an increase of more than 20% since 2008,1 and mortality rates have increased by 14%, bringing the annual number of deaths worldwide from the cancer to more than 611,625.2...
Expert Point of View: Michael S. Lee, MD, and Autumn McRee, MD
DESTINY-CRC01 study discussant, Michael S. Lee, MD, Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, called the findings “most promising” for the subsequent anti-HER2 treatment of HER2-positive metastatic colorectal cancer. The...
Trastuzumab Deruxtecan Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Young Adults With Cancer May Benefit From Germline Genetic Testing
According to the National Cancer Institute, each year, about 70,000 adolescents and young adults (AYA)—those between the ages of 15 and 39—are diagnosed with cancer. Evidence suggests that some cancers found in AYA patients may have unique genetic and biologic features. A study that investigated...
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
Cisplatin/Fluorouracil vs Carboplatin/Paclitaxel in Chemotherapy-Naive Patients With Advanced Anal Cancer
In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive...
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or...
Retrospective Study of Characteristics and Outcomes in Patients With Cancer Hospitalized With COVID-19 in Hubei
In a retrospective cohort study reported in The Lancet Oncology, Yang et al described clinical characteristics, outcomes, and risk factors for mortality in patients with cancer hospitalized with COVID-19 over a 2-month period in Hubei, China. Study Details The study included 205 patients with...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
Meta-analysis of Outcomes With Checkpoint Inhibitor Treatment in Advanced Microsatellite Instability–High Cancers
A meta-analysis of published studies of immune checkpoint inhibition for advanced microsatellite instability–high (MSI-H) cancers—published as a brief report in JAMA Oncology by Petrelli et al—found high activity of these therapies across tumor types and evaluated agents. Study Details The...
Study Finds Blood Test Detects Cancer and Tissue of Origin in Those With or Suspected to Have Cancer
A blood test based on cell-free DNA was able to detect cancer as well as the site of origin in patients with a clinical suspicion of cancer, according to results of the Circulating Cell-Free Genome Atlas (CCGA) study presented at the 2020 American Association for Cancer Research (AACR) Virtual...
Five New Recipients of NCCN Foundation Young Investigator Awards
The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation announced five new recipients for the 10th annual NCCN Foundation Young Investigator Awards Program. The honorees will receive up to $150,000 in funding to study ways to improve care and help find cures for people with...
Plenary Research From the ASCO20 Virtual Scientific Program: Part 1
This week, we’ll be hearing from the authors of three late-breaking abstracts presented in the Plenary program at the ASCO20 Virtual Scientific Program. Their findings highlight significant advances in lung cancer, bladder cancer, and colorectal cancer.
Study Finds Substantial Racial/Ethnic Disparities in Lost Earnings From Cancer Mortality
Disparities in cancer mortality rates between black and white Americans date back more than 60 years. Now, a study by the American Cancer Society comparing person-years of life lost and lost earnings due to premature cancer mortality by race/ethnicity has quantified the economic burden due to...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
